Company: BLLN
Filing Date: 2025-06-20
Form Type: DRS
Source: 0000950123-25-006095
Chunk: 15

Company: BillionToOne, Inc.
Filing Date: 2025-06-20
Form: DRS
Chunk 15
---
 our senior management team or our inability to attract and retain highly skilled scientists, 
 technicians, clinicians, and sales representatives could adversely affect our business.                                 |

| • |     | If our existing laboratory facilities become damaged or inoperable or we are required to vacate our existing facilities, 
 our ability to perform our tests and pursue our research and development efforts may be jeopardized.                     |

| • |     | Our tests in development may not be clinically effective or may never achieve significant commercial market acceptance and 
 our test offerings that we have recently launched may not be commercially successful.                                      |

| • |     | If our products do not meet the expectations of patients and our customers, our operating results, reputation and business 
 could suffer.                                                                                                              |

| • |     | International trade policies, including tariffs, sanctions and trade barriers may adversely affect our business, financial 
 condition, results of operations and prospects.                                                                            |

| • |     | New product development and commercialization involve a lengthy and complex process and we may be unable to develop or 
 commercialize new products on a timely basis or at all.                                                                |

| • |     | Any inability to effectively protect our proprietary technologies could harm our competitive position. |

9

| • |     | We have identified material weaknesses in our internal control over financial reporting. If our remediation of such                                                                                                                                      
 material weaknesses is not effective, or if we identify additional material weaknesses in the future or otherwise fail to develop and maintain effective internal control over financial reporting, our ability to produce timely and accurate financial 
 statements or comply with applicable laws and regulations could be impaired.                                                                                                                                                                             |

The summary risk factors described above should be read together with the text of the full risk factors in the section titled “Risk factors” and the other information set forth in this prospectus, including our financial statements and the related notes. The risks summarized above or described in full elsewhere in this prospectus are not the only risks that we face. Additional risks and uncertainties not presently known to us, or that we currently deem to be immaterial, may also materially adversely affect our business, financial condition, results of operations, and future growth prospects. Channels for disclosure of information Following the closing of this offering, in addition to filings with the Securities and Exchange Commission (SEC), we intend to announce material information to the public via the investor relations page on our website, press releases, public conference calls, public webcasts, our X handle (@BillionToOneInc) and our LinkedIn feed. Any updates to the list of disclosure channels